JPS6236705B2 - - Google Patents
Info
- Publication number
- JPS6236705B2 JPS6236705B2 JP53025724A JP2572478A JPS6236705B2 JP S6236705 B2 JPS6236705 B2 JP S6236705B2 JP 53025724 A JP53025724 A JP 53025724A JP 2572478 A JP2572478 A JP 2572478A JP S6236705 B2 JPS6236705 B2 JP S6236705B2
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- pva
- ascites
- degree
- swelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000012528 membrane Substances 0.000 claims description 79
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 30
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 30
- 206010003445 Ascites Diseases 0.000 claims description 23
- 230000008961 swelling Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000011148 porous material Substances 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000012510 hollow fiber Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 238000004132 cross linking Methods 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000003567 ascitic fluid Anatomy 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229920001600 hydrophobic polymer Polymers 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MTZUIIAIAKMWLI-UHFFFAOYSA-N 1,2-diisocyanatobenzene Chemical compound O=C=NC1=CC=CC=C1N=C=O MTZUIIAIAKMWLI-UHFFFAOYSA-N 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 238000006359 acetalization reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- -1 cerium ion Chemical class 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-M periodate Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 1
- 125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- KUCOHFSKRZZVRO-UHFFFAOYSA-N terephthalaldehyde Chemical compound O=CC1=CC=C(C=O)C=C1 KUCOHFSKRZZVRO-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical class OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Description
æ¬çºæã¯ãå»ççšèŠªæ°Žæ§èçŽ æãšããŠå¥œé©ãªã
ããªããã«ã¢ã«ã³ãŒã«ç³»éžæééæ§èãè
¹æ°Žã®
éèãšããŠçšããèã·ã¹ãã ã«ããè
¹æ°ŽåŠçè£
眮
ã«é¢ããã
è硬å€ïŒå
èçïŒãããã¯è
äžå
šçãåå ã
ãŠãè
¹æ°Žçã«èŠããã§ããæ£è
ã¯çžåœæ°ã«ã®ãŒ
ããåœå
ã§ã¯å¢å åŸåã瀺ããŠãããåŸæ¥ããã®
ãããªæ£è
ã«å¯Ÿãããã°ãã°ãè
¹æ°Žç©¿åºã«ããæ
液æ³ãé©çšãããŠããããããã§ã¯æ£è
ã¯äžæç
ã«æ¥œã«ã¯ãªãããå貯çãæãããŸãè
¹æ°Žäžã®è
çœè³ªçã®æ é€åãåæã«åªå€±ããããšã«ãªããæ£
è
ã®çç¶ã¯è¿ã€ãŠå¢æªããããšãå€ãåé¡ã§ãã€
ããããã«å¯Ÿããæè¿èªå®¶è
¹æ°Žãåé泚ããæ²»ç
æ³ãèšåºçã«è©äŸ¡ããã€ã€ããããã®çºã®æ²»çè£
眮ã®éçºãæãŸããããã«ãªã€ãã
èªå®¶è
¹æ°Žã®åé泚æ³ã¯ãé ãã¯GallupãïŒ1911
幎ïŒãè©Šã¿ãŠããããç¡ä¿®æ£ã®èªå®¶è
¹æ°Žåé泚ã«
ãããã®ã§ãå¹æãå®ãã§ãªãäžè¬ã«çšãããã
ã«å°ããªãã€ãããã®åŸE.AdlercreutzïŒActa.
Med.Scand.161ïŒïŒïŒ1958ïŒïŒR.C.Britton
ïŒArch.Surg.83ïŒ364.1961ïŒããã人工è
èçšé
æè£
眮ãçšããŠãæ¿çž®åé泚ãè¡ãªãéå°æ°Žåè²
è·ã®åé¡ã解決ãããšããããæäœãç
©éã§ã
ããè£
眮ã®èœåãåé¡ã§ãéçµæžçã§ããããšç
ãã顧ã¿ãããªãã€ãããããããã®æ¹æ³ã§ã¯è
¹
æ°Žäžã«çŽ°èã巚倧现èçäžèŠç©ãå«ãŸããå Žå
ã«ããããããæ¿çž®ããŠãè¡ç®¡å
ã«æ»ãããšã«ãª
ãåé¡ã§ãããããã«å¯Ÿãæè¿è
¹æ°Žãããããã
éããŠç现èã现èãé€å»ããŠåŸãæ¿çž®åé泚
ããæ¹æ³ããè©Šã¿ãããã®çš®çšéã«ããå®å
šã«ã
ãã€æ±çšçã«çšããããåŠæ³ãšããŠæ³šç®ããã€ã€
ããã
ãããç®çã«å¯ŸããäŸãã°ç¹éæ51â140387å·
ã«ãŠéåšãšæ¿çž®åšãåããè
¹æ°ŽåŠçè£
眮ãææ¡
ãããŠããã該çºæã§ã¯å
·äœçã«ã¯éèãšããŠ
ã»ã«ããŒã¹ã¢ã»ããŒãèã瀺ãããŠããããã®è
ã¯è
¹æ°Žã®éèãšããŠäžå¿ç®çãéããæ§èœãæ
ããããçäœé©åæ§ãèç±æ§ãèå§æ§çãäžåå
ã§ããã䜿çšã«éããŠçš®ã
ã®å¶éãå¿
èŠãšãã
ããããã§çäœé©åæ§ã¯ã被åŠçè
¹æ°Žäžã®èçœç
ã®å€æ§ã®æç¡ã«é¢ä¿ããèç±æ§ã¯é«å§èžæ°æ»
èã
ãèãæäŸã§ãããåŠãã®åé¡ã«é¢ä¿ãããé«å§
èžæ°æ»
èããèã¯ããã«ããªã³ããšãã¬ã³ãªããµ
ã€ãã¬ã¹çã®è¬å€ãå«ãŸãªããšããç¹ã§æ¬ç®çã«
ã¯æãŸãããã®ã§ããã
æ¬çºæè
ãã¯ãããã芳ç¹ããæ¬è³ªçã«èŠªæ°Žæ§
ã倧ããçäœé©åæ§ã«ããããŠããããã€ååŠåŠ
çã«ãã€ãŠèç±æ§ãæ¹åã§ããçŽ æãšããŠPVA
ç³»èãæ€èšããçµæãPVAç³»èã®ããã«èŠªæ°Žæ§
ã®å€§ããªç©è³ªã¯å«æ°Žçã倧ããéæ°Žæ§ãããããŠ
ãããã®ã®åŒ·åºŠïŒèå§æ§ïŒãå£ãããèå§æ§ãæ¹
åãããšéã«èŠªæ°Žæ§ãäœäžãããšããåé¡ããã€
ãããPVAç³»èã«ç¹å®ã®æ§é ãä»äžããããšã«
ãããé«å§èžæ°æ»
èå¯èœãªéèãåŸãããããš
ãèªãæ¬çºæãå®æããã
ããªãã¡æ¬çºæã¯å¹³åååŸãã0.01ãïŒÎŒã®ç¯
å²ã«ããåäžå€å質æ§é ãæãããã€ãã®èšæœ€åºŠ
Ïã1.0âŠÏâŠ1.2ãã€ã³ã°ã¢ãžãŠã©ã¹æ¯ïŒŽãâ§
0.3ïŒããã§ãããšã¯100âåã³40âæ°Žäžã«ãã
ãã€ã³ã°ã¢ãžãŠã©ã¹ã®æ¯Y100ïŒY40ãæå³ããïŒ
ã§ãã105ã140âã§é«å§èžæ°æ»
èå¯èœãªPVAç³»
éžæééæ§èãå
èµããéåäœãšãäžèšéå
äœã«ãã€ãŠéãããè
¹æ°Žãæ¿çž®ããéžæééæ§
èãå
èµããæ¿çž®åäœããæ§æãããããšãç¹åŸŽ
ãšããè
¹æ°ŽåŠççšè£
眮ã§ãããäžè¿°ã®å€å質æ§é
ã¯äžäžåã®é»é¡èŠ³å¯ã«ããèªããããæ§é ã§ã
ãã
æ¬æ¥ãèã«ããè
¹æ°Žã®éã«ããç现èã®é€å»
æäœã¯ãç®ããŸããèµ·ãæãé£äœæ¥ã§ããããäž
èšããæ¬çºæã«ããèã®å€å質æ§é ã«ããã«æå¹
埮现åå¹³åååŸãã0.01ãïŒÎŒãªãPVAç³»éžæé
éæ§èãçšããã°ãäºæ³å€ã«ç®ããŸããçããã«
é«ãã©ãã¯ã¹ã§ãåé¢å¯èœã§ããããšãèŠåºã
ãããã®æå¹å¹³åååŸãïŒÎŒä»¥äžã®ãã®ã§ã¯ãè¡
çãç现èãééãããå¯èœæ§ã倧ã§ããäžé©åœ
ã§ãããå0.01Ό以äžã§ã¯æçšãªèçœè³ªã®ååç
ãæªããåé¢èœå³ã¡åŠçèœåãæ¥æ¿ã«äœäžããçº
ã«å¥œãŸãããªãã
該èã¯ããã«å¥œãŸããã¯æå¹å¹³åååŸ0.01ã
0.2ÎŒã®å€å質æ§é ãæããã該èã«ããã°è
¹æ°Ž
çæ£è
ã«å¯Ÿããèªå®¶è
¹æ°Žéåé泚治çãè¡ãé
ã«çŽ°èé¡ãšå
±ã«çŽ°èé¡ããé€å»ããããšãã§ãã
çç¶ã®æ¹åã«èããå¹æãæåŸ
ã§ããããããæ§
é ã¯æ¬çºæã®èãååŸã®èª¿æŽã容æã§ããããšã
ãéæã§ããããšã§ãããæå¹å¹³åååŸã0.2ÎŒ
以äžã«ãªããšã现èé¡ã«å¯Ÿããé»æ¢çãäœäžã
ããããã§ã®æå¹ååŸã¯ãèã«å¯Ÿããçœè¡çãå
åé100äžçšåºŠã®èçœåã³0.2ÎŒã®ç²åãå«ãã©ã
ãã¯ã¹çã®é»æ¢çã«ããè©äŸ¡ããã
äžè¿°ããå€å質æ§é ã¯åŸè¿°ããæ¹æ³ã§é»é¡èŠ³å¯
ããèªããããæ§é ã§ãããããããªããèã®å
éšæ§é ã¯é»é¡èŠ³å¯ã§èªããããæ§é ã®ã¿ã§è¡šãã
ãããã®ã§ã¯ãªããäŸãã°ééæåã®ç²ååŸãã
èãããšãé»é¡ã§èªããããæ§é ã®ä»ã«ãå¥ã®åŸ®
现åæ§é ããããšèããã®ã劥åœãšããããæ¬çº
æã«ããèã«ãããŠãé»é¡ããèªãããã0.01ã
ïŒÎŒã®å€å質æ§é ã®äžã«ãå皮溶液ã®ééæ§è©Šéš
ãã0.01ãïŒÎŒã®åŸ®çŽ°åããããšèããããã®
ã§ã該埮现åãæå¹åŸ®çŽ°åãšããã該æå¹åŸ®çŽ°å
ã¯é»é¡èŠ³å¯ããèŠãããæ§é ãšã¯å¥ç°ã®ãã®ã§ã
ãã
æ¬çºæã®èã¯äžèšããå€å質æ§é ã«ããã«ç¹å®
ã®èšæœ€åºŠããã€ããšãç¹åŸŽãšãããæ¬çºæã®ç®ç
ã«å¯ŸããŠèã¯é«ééæ§ãšå
±ã«é«ãèå§æ§ãæãã
ããšãå¿
èŠã§ããã該èå§æ§ã«å¯ŸããŠèãç¹å®ã®
èšæœ€åºŠãæããããšãå¿
èŠã§ããããšãèªããã
ããã§ãèšæœ€åºŠÏãšã¯ã¡ã³ãã¬ã³ã®æé¢ã®å€åŸ
ïŒäžç©ºç³žïŒåã¯åã¿æ¹åã®é·ãïŒå¹³èïŒã®dryã«
察ããwetã®æ¯ïŒåïŒã瀺ãããã®èšæœ€åºŠã¯1.0âŠ
ÏâŠ1.2ã§ããããšãå¿
èŠã§ãããÏã1.2ãã倧
ãããšèå§æ§ãä»ã®æ©æ¢°çç¹æ§ãäžè¶³ããããã«
å§åäžæãšå
±ã«èã®å€åœ¢ããããããããééæ§
ã倧巟ã«å€åãããããšã«ãªãã
ãããdryã®æž¬å®ã¯25ââRH60ïŒ
ã«24æéæŸ
眮åŸè¡ãªããWetã®æž¬å®ã¯25ââæ°Žäž24æéæŸçœ®
åŸè¡ãªããåŸæ¥ã®æè¡ã§ã¯PVAç³»èã®ãããªèŠª
æ°Žæ§ã®å€§ããªèã¯å¿
ç¶çã«èšæœ€åºŠã倧ãšãªããã
ã®å€ã1.2å以äžãéåžžã¯1.4å以äžã®ãã®ããåŸ
ãããªãã€ããå³ã¡èŠªæ°Žæ§ã®å€§ãªãæ§é ã¯å«æ°Žç¶
æ
ã§ã¯å¿
ç¶çã«åœ¢æ
ãèšæœ€å€åœ¢ããã®ã§èšæœ€åºŠã¯
1.4å以äžãšãªããããåŸãªãã€ãããã®ããèš
最床ãå°ãããã®ãšããã«ã¯çŽ æãçæ°Žæ§ããªã
ãŒããéžã°ãªããã°ãªããªããšä¿¡ããããŠããã
ãããã«æ¬çºæè
ãã¯ã芪氎æ§ã倧ã§ãã€èšæœ€åºŠ
ãå°ããªPVAç³»èãåŸãããšã«æåãã芪氎æ§
ããªããŒãšçæ°Žæ§ããªããŒã®ç¹æ§ã䜵æããåŸæ¥
ãªãç»æçãªæ°ããPVAç³»èãæäŸããããšã
ã§ããããŸãèšæœ€åºŠã¯äžè¬çã«ã¯çæ°Žæ§ã瀺ãå°º
床ãšããªããããªã¢ã¯ãªããããªã«ç³»ïŒã»ã«ããŒ
ã¹ã¢ã»ããŒãç³»ããªããŒã¯çæ°Žæ§ã§ããããšã
ããèšæœ€åºŠã®ã¿ãèããã°ãåçšåºŠã®ãã®ãšãªã
ããã®æå³ããããšããæ¬çºæã®PVAç³»èã§ã¯
æããã«ç°ãªãç¹ã«æ³šæãã¹ãã§ããã
æ¬çºæã®èã®èšæœ€åºŠã¯ãPVAç³»èãååºæµŽã
åºãåŸã®ä»»æã®æ®µéã§ãã«ã ã¢ã«ãããïŒã¢ã»ã
ã¢ã«ãããïŒãã³ãºã¢ã«ããããªã©ã®ã¢ãã¢ã«ã
ããïŒæãã¯ã°ã«ã¿ã«ã¢ã«ãããïŒã°ãªãªãã¶ãŒ
ã«ïŒPVAãéæ²çŽ é
žã€ãªã³ãã»ãªãŠã ã€ãªã³ã§
é
žåå解ããŠåŸãããPVAãžã¢ã«ããããªã©ã®
ãžã¢ã«ãããã§ã¢ã»ã¿ãŒã«åãããããšã¹ãã«
åïŒãšãŒãã«åã®PVAå€æ§åŠçãè¡ãããšã«ã
ã調æŽã§ããããããååŠçå€æ§åŠçã«ãããŠã
ïŒçš®é¡ä»¥äžã®å€æ§å€ãçšããããšãå¿è«å¯èœã§ã
ããåå¯æ¬¡çã«ç±åŠçæäœã䜵çšããããšãã§ã
ãã
æ¬çºæã®PVAç³»éèã¯ãã»ã«ããŒã¹ã¢ã»ã
ãŒãïŒããªã¢ã¯ãªããããªã«çã®ä»ã®éå€éè
ã«ã¿ãããªãããããèç±æ§ïŒé«æž©ç¹æ§ãå
Œãå
ããããšãã§ããã
æ¬çºæã®ç®çãšããå»ççšèã¯æº¶åºç©ã®ãªãã
ãšãšæ»
èåŠçãè¡ãããšãå¿
èŠã§ããã溶åºç©ã¯
èã70âïŒæéæ°ŽäžåŠçããŠæº¶åºããç©è³ªã®éã
è©äŸ¡ãããã®ã§ãããããã¯èçŽ æã®èç±æ§ãšå¯
æ¥ãªé¢ä¿ããããæ»
èåŠçã¯ãå
¬ç¥ã®ãã«ããªã³
æ°Žæ»
èããšãã¬ã³ãªããµã€ãã¬ã¹æ»
èã§ãå¯èœã§
ãããããããªãããããè¬å€ã«ããæ»
èã¯ãã®
æ®åéã®æ£è
ã«å¯Ÿããæªåœ±é¿ãæžå¿µããã€ã€ã
ãããããç¹ãããå»ççšèã®æ»
èãšããŠã¯105
ã140âã®é«å§èžæ°æ»
èåã¯105ã140âã®æ°Žåã¯
ççé£å¡©æ¶²ååšäžã§é«å§èžæ°ã§ããããšãæãŸã
ãããã®ãããªé«æž©æ¹¿ç±åŠçã«å¯ŸãåéèãšããŠ
ã®æ§èœãä¿æã§ãããåŠãã¯ãå
šããã®èç±æ§ã«
äŸåããã
æ¬çºæè
ãã¯ãäžè¿°ããæ¬çºæã®éèã«å¯Ÿ
ããããã«ãããé«åºŠã®èç±æ§ãä»äžã§ãããåŠ
ãæ€èšããçµæã€ã³ã°ã¢ãžãŠã©ã¹æ¯ïŒŽãT.â§0.3
奜ãŸããã¯T.â§0.5ãæºè¶³ããã°ã121â20åã®é«
å§èžæ°æ»
èã«ååèããããèã«ããããšãã§ã
ãããšãèŠãåºãããå¿è«ãããèã¯70âã§ã®æº¶
åºç©ã®ã¬ãã«ãååæºè¶³ããããã®ã§ããããã
ã§ãããšã¯ãå100âåã³40âæ°Žäžã«ãããã€
ã³ã°ã¢ãžãŠã©ã¹ïŒPVAç³»ããªããŒã®ååéã®æ¶
æ©åºŠã瀺ãïŒã®æ¯Y100ïŒY40ãæå³ãããã¯è
å§ïŒèç±æ§ã瀺ãäžã€ã®å°ºåºŠã§ãããâ§0.3ãª
ãèã¯121â20åéã®èžæ°åŠçã«ãã€ãŠããå®çš
äžåé¡ãšãªãçšã®åœ¢ç¶ã®å€åã¯ã¿ãããâ§0.5
ãªãèã§ã¯ååŠçã«ãã圢ç¶ã®å€åã¯å
šãã¿ãã
ãªããâ§0.3ãæºè¶³ããæ¬çºæã®PVAç³»éè
ã¯140âãŸã§ã®æ¹¿ç±åŠçãæ°åããè¿ããŠããã
ã®æ§èœã®å€åã¯å
šãã¿ãããªããšããé©ãã¹ãç¹
æ§ãæããŠããã
ã€ã³ã°ã¢ãžãŠã©ã¹æ¯ïŒŽã¯ãåè¿°ããèšæœ€åºŠèª¿æŽ
ã®ããã®ååŠçå€æ§åŠçã®ãã¡ååéæ¶æ©åå¿ã
å°ããšããã®äžéšãšããŠçšããããšã«ããéæã§
ãããæ¶æ©åŠçãšããŠã¯ãPVAã®ååéæ¶æ©ã
圢æãããã®ãäŸãã°ãã°ã«ã¿ãŒã«ã¢ã«ãããïŒ
ã°ãªãªãã¶ãŒã«ïŒãã¬ãã¿ã«ã¢ã«ãããçã®ãžã¢
ã«ãããã«ããæ¶æ©ãããšãã¬ã³ãžã€ãœã·ã¢ããŒ
ãïŒããªã¬ã³ãžã€ãœã·ã¢ããŒãçã®ãžã€ãœã·ã¢ã
ãŒãã«ããæ¶æ©ãããªã°ãªã³ãŒã«é
žãšã¹ãã«ã«ã
ããšã¹ãã«æ¶æ©ãçãçšããããããããã®å
ã§
åå¿ã®å®¹æãã®ç¹ããã¯ãžã¢ã«ãããæ¶æ©ãçšã
ãã®ãæå©ã§ãããç¹ã«ã°ã«ã¿ãŒã«ã¢ã«ãããã
奜ãŸããã以äžè¿°ã¹ãåŠããè
¹æ°Žéåäœã«çšã
ãPVAç³»èã¯PVAã®èŠªæ°Žæ§ãæãããŸãŸãèšæœ€
床ã«ãããŠã¯çæ°Žæ§ããªããŒã®ç¹æ§ã瀺ããšãã
å
šãç¹ç°ãªæ§é ãæãããã®ãã芪氎æ§ã倧ãã
ãã€èå§æ§ã倧ãããšããããããæ§èœãæã
ãããŸããã®èã¯105ã140âã®é«å§èžæ°æ»
èåŠç
ããããšãã§ãããã®å Žåã§ãéèãšããŠã®æ§
èœäœäžã¯å
šããªãããããäºå®ã¯åŸæ¥ã®ãããªã
èã«ãç¥ãããŠããªãããšã§ããã次ã«æ¬çºæã«
ããæ¿çž®èã«ã€ããŠèª¬æããã
æ¬çºæã«ããæ¿çž®èã¯ãéæ°Žéãå°ããšã0.2
mlïŒhr.atm.cm2ïŒinvitroèžçæ°ŽïŒã§ãããã€åç»
ååéã45000以äžã®éžæééæ§èã§ããããç¹
éæ51â140387å·ã«èšèŒãããŠããããã«äžè¬ã«
人工è
èã«çšããããŠããèãçšããããšãã§ã
ããäžã§ãåè¿°ã®éçšã®PVAç³»èãšåçš®ã®çŽ
æåã³ãšãã¬ã³å«éã10ã50ã¢ã«ïŒ
ãããªããšã
ã¬ã³âããã«ã¢ã«ã³ãŒã«å
±éåäœïŒEVAïŒãã
ãªãèãçšããããšã奜ãŸããã該èã¯æ§æç²å
ãå®è³ªç也ç¥èã®é»åé¡åŸ®é¡èŠ³å¯ã«ãããŠæ±ãã
ããå¹³åç²ååŸã100ã10000â«ãã奜ãŸããã¯
500ã7000â«ã®ç¯å²ã«ããã該ç²åãçžäºã«æ¥å
ããæ§é ãæããããããæ§é ã®PVAç³»èãäž
è¿°ããéæ°Žæ§ãšåç»ååéãæãè
¹æ°Žã®æ¿çž®çšè
ãšããŠäœ¿çšã§ãããéæ°Žéã0.2mlïŒhr.atm.cm2以
äžã§ã¯å€§ããªèé¢ç©ãé·æéãå¿
èŠãšãªãå®çšç
ã§ãªããåç»ååéã45000以äžã§ã¯æçšæåã§
ããèçœé¡ã®åªå€±ãèµ·ãé©åœã§ãªãã
以äžè¿°ã¹ãPVAç³»ã®éçšèãšEVAã®æ¿çž®è
ã¯äŸãã°ç¹éæ52â123385ïŒç¹é¡æ51â107089
ïŒç¹éæ53â31580ïŒåã³å52â152877å·ã«ç€ºãã
ã補é æ³ã«ãã補é ããããšãã§ããã
æ¬çºæã«ãããŠãéçšèåã³æ¿çž®çšèãäžç©º
糞åã¯å¹³èçã®åœ¢æ
ã§çšããåçš®æ§é ã®éåäœ
åã³æ¿çž®åäœãæ§æãããååäœã¯ç¬ç«ã®ããŠãž
ã³ã°ã«å容ãããŠããåäžã®ããŠãžã³ã°ã«å容ã
ããŠãããããããã®æ§æåäœã¯å
¬ç¥ã®ãã³ã茞
液åè·¯çãšäžäœã«ããŠãå®éã®è
¹æ°ŽåŠçã«äŸã
ãã以äžå®æœäŸã«ããæ¬çºæã説æããã
å®æœäŸïŒãïŒåã³æ¯èŒäŸïŒïŒïŒ
ã±ã³å床98.5ïŒ
ãDP2400ã®PVAãšãååé
1000ã®PEGãPVAã«å¯Ÿã100ïŒ
æ··åãã100âã§
å ç±æº¶è§£ããPVAæ¿åºŠ14.5ïŒ
ã®åäžãªæ°Žæº¶æ¶²ã調
æŽããã
ãã®çŽ¡ç³žå液ãç°ç¶ããºã«ããNaOHïŒ
Na2SO4ïŒ70ïŒ240ïœïŒã®ååºæµŽã«æåºããŠäžç©º
糞ãããã次ãã§ã該äžç©ºç³žãã°ã«ã¿ã«ã¢ã«ãã
ãïŒH2SO4ïŒNa2SO4ç³»ã®æ¶æ©åŠç济äžã§70âã
ïŒæé浞挬åŠçããããã«25âãïŒæéæµæ°ŽæŽã
ãŠPEGãå®å
šã«é€å»ã埮现åæ§é ã圢æããã
ãã®åŸå®€æž©ã§é¢šä¹Ÿã也ç¥äžç©ºç³žãåŸãã
åŸãããäžç©ºç³žã«ã€ããŠãèšæœ€åºŠÏãã€ã³ã°ã¢
ãžãŠã©ã¹æ¯ïŒŽã該äžç©ºç³žã®120âã20åéé«å§èž
æ°æ»
èåŸã®éæ°Žæ§åã³èå§æ§ãè¡šâïŒã«ç€ºããã
ãªããèæ°Žæ§ãšã¯wetç¶æ
ã®äžç©ºç³žã®å
åŽãå
å§ãããšãã®ç Žè£å§ã§ããã
The present invention is suitable as a medical hydrophilic membrane material,
The present invention relates to an ascites treatment device using a membrane system using a polyvinyl alcohol-based permselective membrane as an ascites membrane. A considerable number of patients suffer from ascites due to liver cirrhosis, internal cancer, renal failure, etc., and the number is increasing in Japan. Conventionally, drainage of fluid through ascitic puncture has often been applied to such patients, but although this provides temporary relief to the patient, it tends to re-accumulate, and nutrients such as proteins in ascites are lost. At the same time, the patient's symptoms often worsen, which is a problem. In contrast, a treatment method of reinjecting autologous ascitic fluid intravenously has recently been clinically evaluated, and the development of a treatment device for this purpose has become desirable. Re-infusion of autologous ascites has been widely used by Gallup et al. (1911
(2012) attempted this, but it was based on repeated intravenous injection of autologous ascitic fluid without modification, and its effectiveness was uncertain, so it was not widely used. Afterwards E. Adlercreutz (Acta.
Med.Scand. 161 , 1, 1958), R.C. Britton
(Arch. Surg. 83.364.1961 ) attempted to solve the problem of excessive fluid load by performing concentrated re-infusion using an artificial kidney dialysis machine, but the operation was complicated and the machine's capacity was also problematic. However, it was not considered because it was uneconomical. Moreover, this method poses a problem in that if the ascites contains unnecessary substances such as bacteria and giant cells, these will also be concentrated and returned to the blood vessels. In contrast, a method has recently been attempted in which ascitic fluid is filtered in advance to remove cancer cells and bacteria, and then concentrated and re-injected intravenously, making it safer for this type of use.
It is also attracting attention as a widely used treatment method. For this purpose, for example, Japanese Patent Laid-Open No. 140387/1987 proposes an ascites treatment device equipped with a filter and a concentrator. In this invention, a cellulose acetate membrane is specifically shown as the membrane. Although this membrane has the ability to achieve its intended purpose as a membrane for ascites, it has insufficient biocompatibility, heat resistance, pressure resistance, etc., and various restrictions are required when using it. Here, biocompatibility is related to the presence or absence of denaturation of proteins in the ascites to be treated, and heat resistance is related to whether a membrane sterilized by high-pressure steam can be provided. Autoclaved membranes are desirable for this purpose in that they do not contain chemicals such as formalin or ethylene oxide gas. From this perspective, the present inventors discovered PVA as a material that is inherently hydrophilic and has excellent biocompatibility, and whose heat resistance can be improved through chemical treatment.
As a result of examining the system membranes, we found that highly hydrophilic substances such as PVA membranes have a high water content and excellent water permeability, but have poor strength (pressure resistance), but improving pressure resistance conversely reduces hydrophilicity. However, the present invention was completed after recognizing that a permeable membrane that can be sterilized by high-pressure steam could be obtained by imparting a specific structure to a PVA-based membrane. That is, the present invention has a uniform porous structure with an average pore diameter in the range of 0.01 to 2ÎŒ, a swelling degree Ï of 1.0âŠÏâŠ1.2, and a Young's modulus ratio Tâ§
0.3 (T here means the Young modulus ratio Y 100 /Y 40 in water at 100°C and 40°C)
The unit consists of a permselective membrane with a built-in PVA-based permselective membrane that can be autoclaved at 105 to 140°C, and a concentration unit with a permselectively membrane that concentrates the ascites filtered through the persunit. This is an ascites treatment device characterized by: The above-mentioned porous structure is a structure recognized by electron microscopic observation at a magnification of 10,000 times. Originally, removing cancer cells through ascites through a membrane is a difficult task that tends to cause clogging, but the porous structure of the membrane according to the present invention has an effective micropore average diameter of 0.01 to 2Ό. We have unexpectedly discovered that by using a PVA-based permselective membrane, separation is possible at high flux without clogging. If the effective average pore diameter is 2 Ό or more, it is unsuitable because there is a high possibility that blood cells or cancer cells will pass through. Further, if it is less than 0.01Ό, the recovery rate of useful proteins is poor, and the separation ability, that is, the processing ability, decreases rapidly, which is not preferable. The membrane more preferably has an effective average pore diameter of 0.01 to
It has a porous structure of 0.2Ό. According to this membrane, bacteria can be removed along with cells when treating patients with ascites with repeated intravenous injection of autologous ascites.
It can be expected to have a significant effect on improving symptoms. Such a structure can be achieved in the membrane of the present invention because the pore size can be easily adjusted. Effective average pore diameter is 0.2Ό
If the amount exceeds that level, the inhibition rate against bacteria will decrease. The effective pore size here is evaluated by the rejection rate of latex, etc. containing white blood cells, proteins with a molecular weight of about 1 million, and particles of 0.2Ό against the membrane. The porous structure described above is a structure that can be observed by electron microscopy using the method described below. However, the internal structure of the membrane is not expressed only by the structure observed by electron microscopy; for example, considering the particle size of the permeable component, it is thought that there is another micropore structure in addition to the structure observed by electron microscopy. is considered appropriate. In the film according to the present invention, 0.01~ observed by electron microscopy
Based on the permeability test of various solutions, it is thought that there are micropores of 0.01 to 2Ό on the 2Ό porous structure, so these micropores are considered as effective micropores. The effective micropores have a structure different from that seen through electron microscopy. The membrane of the present invention is characterized by having a specific degree of swelling in addition to the above-mentioned porous structure. It has been recognized that for the purposes of the present invention it is necessary for the membrane to have high pressure resistance as well as high permeability, and it is necessary for the membrane to have a certain degree of swelling for the pressure resistance.
Here, the degree of swelling Ï indicates the ratio (times) of wet to dry of the outer diameter of the cross section of the membrane (hollow fiber) or the length in the thickness direction (flat membrane). This degree of swelling is 1.0âŠ
It is necessary that ÏâŠ1.2. When Ï is larger than 1.2, pressure resistance and other mechanical properties are insufficient, and the membrane is likely to deform as pressure increases, resulting in wide fluctuations in permeability. Dry measurements are performed after being left at 25°C and RH 60% for 24 hours, and wet measurements are made after being left in water at 25°C for 24 hours. With conventional techniques, highly hydrophilic membranes such as PVA-based membranes inevitably have a high degree of swelling, and it has only been possible to obtain a swelling value of 1.2 times or more, usually 1.4 times or more. In other words, the shape of a large hydrophilic structure inevitably swells and deforms in a water-containing state, so the degree of swelling is
It had to be more than 1.4 times as large. Therefore, it was believed that in order to reduce the degree of swelling, the material must be selected from hydrophobic polymers.
However, the present inventors succeeded in obtaining a PVA-based membrane with high hydrophilicity and low degree of swelling, creating a new and unprecedented PVA-based membrane that has both the characteristics of hydrophilic and hydrophobic polymers. I was able to provide it. In addition, swelling degree is generally a measure of hydrophobicity, and polyacrylonitrile-based and cellulose acetate-based polymers are hydrophobic, so if we consider only swelling degree, they are about the same, but what does it mean? However, it should be noted that the PVA-based membrane of the present invention is clearly different. The degree of swelling of the membrane of the present invention is determined by adding monoaldehyde such as formaldehyde, acetaldehyde, or benzaldehyde, or glutaraldehyde, glyoxal, or PVA to periodate ion or cerium ion at any stage after the PVA membrane leaves the coagulation bath. It can be adjusted by acetalization with a dialdehyde such as PVA dialdehyde obtained by oxidative decomposition, or by PVA modification treatment such as esterification or etherification. In these chemical modification treatments,
Of course, it is possible to use two or more types of modifiers, and a heat treatment operation can also be used in combination. The PVA-based membrane of the present invention can have excellent heat resistance and high-temperature properties not found in other ultrafiltration membranes such as cellulose acetate and polyacrylonitrile. The medical membrane targeted by the present invention must be free of eluates and must be sterilized. The amount of eluted substances is evaluated by treating the membrane in water at 70°C for 1 hour and evaluating the amount of substances eluted, which is closely related to the heat resistance of the membrane material. The sterilization process can also be performed by known formalin water sterilization or ethylene oxide gas sterilization. However, there is a growing concern that sterilization using these drugs may have an adverse effect on patients due to the residual amount of the drugs. From this point of view, 105 is recommended for sterilization of medical membranes.
It is desirable to be able to perform high-pressure steam sterilization at ~140°C or high-pressure steaming at 105-140°C in the presence of water or physiological saline. Whether or not the membrane can maintain its performance as a semipermeable membrane under such high-temperature, moist heat treatment depends entirely on its heat resistance. The present inventors investigated whether such a high degree of heat resistance could be imparted to the membrane of the present invention described above, and as a result, the Young modulus ratio T was T. 0.3.
It has been found that, preferably, if T. Of course, such a membrane has a sufficiently satisfactory level of eluate at 70°C. T here means the ratio of Young's modulus (indicating the degree of crosslinking between molecules of PVA polymer) Y 100 /Y 40 in water at 100°C and 40°C, which is a measure of pressure resistance and heat resistance. It is. Even after steam treatment at 121°C for 20 minutes, the film with Tâ§0.3 did not show any change in shape that would pose a practical problem.
The film shows no change in shape due to the same treatment. The PVA membrane of the present invention, which satisfies Tâ§0.3, has the surprising property that no change in performance is observed even after repeated heat-and-moisture treatment up to 140°C several times. The Young's modulus ratio T can be achieved by using an intermolecular crosslinking reaction as at least a part of the chemical modification treatment for controlling the degree of swelling described above. As a crosslinking treatment, a substance that forms intermolecular crosslinks of PVA, such as glutaraldehyde,
Crosslinking using dialdehydes such as glyoxal and terephthalaldehyde, crosslinking using diisocyanates such as phenylene diisocyanate and tolylene diisocyanate, and ester crosslinking using thioglycolic acid esters are used. Among these, it is advantageous to use dialdehyde crosslinking from the viewpoint of ease of reaction, and glutaraldehyde is particularly preferred. As mentioned above, the PVA-based membrane used for the ascites membrane has a completely unique structure that exhibits the characteristics of a hydrophobic polymer in swelling degree while retaining the hydrophilic properties of PVA. It has excellent performance with high strength. Moreover, this membrane can be subjected to high-pressure steam sterilization at 105 to 140°C, and even in this case, there is no deterioration in performance as a membrane. This fact is unknown for any conventional membrane. Next, the concentration membrane according to the present invention will be explained. The concentration membrane according to the invention has a water permeability of at least 0.2
ml/hr.atm.cm 2 (in vitro distilled water) and a permselective membrane with a molecular weight cut off of 45,000 or less, but it is generally used in artificial kidneys as described in JP-A-51-140387. A membrane that has been prepared can be used. Among these, it is preferable to use a membrane made of the same material as the overused PVA membrane mentioned above and an ethylene-vinyl alcohol copolymer (EVA) having an ethylene content of 10 to 50 mol%. The membrane preferably has constituent particles having an average particle diameter of 100 to 10,000 Ã
as determined by electron microscopic observation of a substantially dry membrane.
The particle diameter is in the range of 500 to 7000 Ã
and has a structure in which the particles are bonded to each other. A PVA-based membrane having such a structure has the above-mentioned water permeability and molecular weight cutoff, and can be used as a membrane for concentrating ascites. If the water permeability is less than 0.2 ml/hr.atm.cm 2 , a large membrane area or a long time will be required, which is not practical, and if the molecular weight cut-off is more than 45,000, proteins, which are useful components, will be lost, which is not appropriate. The PVA-based overuse membrane and EVA concentration membrane mentioned above are disclosed in, for example, Japanese Patent Application Laid-Open No. 52-123385 and Japanese Patent Application No. 51-107089.
(Japanese Unexamined Patent Publication No. 53-31580) and No. 52-152877. In the present invention, the overflow membrane and the concentration membrane are used in the form of hollow fibers or flat membranes to constitute overflow units and concentration units of various structures. Each unit may be housed in separate housings or in a single housing. These structural units are integrated with a known pump infusion circuit, etc., and are used for actual treatment of ascites. The present invention will be explained below with reference to Examples. Examples 1 to 3 and Comparative Examples 1 and 2 PVA with saponification degree of 98.5%, DP2400, and molecular weight
1000 PEG was mixed with PVA at 100% and dissolved by heating at 100°C to prepare a homogeneous aqueous solution with a PVA concentration of 14.5%. This spinning stock solution is passed through an annular nozzle using NaOH/
Hollow fibers were obtained by precipitation in a coagulation bath containing Na 2 SO 4 =70/240g/. Next, the hollow fibers were heated at 70°C in a crosslinking treatment bath of glutaraldehyde/H 2 SO 4 /Na 2 SO 4 system.
It was immersed for 5 hours and then washed with running water at 25°C for 3 hours to completely remove PEG and form a microporous structure.
Thereafter, the fibers were air-dried at room temperature to obtain dry hollow fibers. Table 1 shows the degree of swelling Ï, Young's modulus ratio T, water permeability and pressure resistance of the hollow fibers after autoclaving at 120°C for 20 minutes. Note that water resistance is the bursting pressure when pressurizing the inside of the hollow fiber in a wet state.
ãè¡šã
è¡šâïŒã«ç€ºãå®æœäŸåã³æ¯èŒäŸããæããªãã
ã«èšæœ€åºŠÏã1.0âŠÏâŠ1.2ãã€ã³ã°ã¢ãžãŠã©ã¹æ¯
ãâ§0.3ãæºè¶³ããäžç©ºç³žã®é«å§èžæ°æ»
èåŸ
ã®éæ°Žæ§åã³èå§æ§ãåªããŠããã
å®æœäŸ ïŒ
ã±ã³å床98.5ïŒ
ïŒDP2400ã®PVAãšååé1000
ã®PEGïŒ95ïŒ
ïŒPVAïŒã100âå ç±æº¶è§£ããPVA
æ¿åºŠ16ïŒ
ã®çŽ¡ç³žå液ãããããç°ç¶ããºã«ããã
æŒãåºãéåžžã®æ¡ä»¶äžã§äžç©ºç³žãããã次ãã§åŸ
ãããäžç©ºç³žãã°ã«ã¿ã«ã¢ã«ãããïŒH2SO4ïŒ
Na2SO4ïŒïŒïŒ30ïŒ200ïœïŒã®åŠç济ã«70ââïŒ
æé浞挬ãæ¶æ©åŠçããåŸãåžžæž©æ°ŽæŽãæŽã«85â
ã«ãŠïŒæéæŽæ»ããŠPEGãé€å»ãã埮现åæ§é
ã圢æããããã®åŸå®€æž©ã§é¢šä¹Ÿã也ç¥äžç©ºç³žãåŸ
ããåŸãããäžç©ºç³žã®å€åŸã¯800ÎŒãèå200ÎŒã§
ãã€ããåŸãããäžç©ºç¹ç¶ã®ã€ã³ã°ã¢ãžãŠã©ã¹ã¯
Y40ïŒ7.0KgãY100ïŒ6.2Kgã§ãããã€ã³ã°ã¢ãžãŠã©
ã¹æ¯ïŒŽã¯0.89ã§ãã€ããæ¬äžç©ºç¹ç¶ãçšããŠæå¹
èé¢ç©0.5m2ã®éè£
眮ãäœè£œãã121â20åéé«
å§èžæ°æ»
èãïŒåç¹°ãè¿ãããã®æ§èœå€åãã¿ã
ããå
šãèæ§èœã¯æãªãããããšã¯ãªãã€ãã
ãã®dryäžç©ºç³žã®æé¢ãé»é¡èŠ³å¯ãããšããã
åäžãªåŸã瀺ããããã暪æé¢ã«åäžã«é
åãã
ãŠããã®ãèªãããåèšæœ€åºŠÏã¯1.04ã§ãã€ãã
ãã®äžç©ºç¹ç¶ãçšããŠãæå¹èé¢ç©1.0m2ã®é
è£
眮ãäœæããã
åãæ¿çž®çšèãšããŠã¯ããšãã¬ã³å«é33ã¢ã«ïŒ
ã®äººå·¥è
èçšã®EVAäžç©ºç³žèãçšããããã®äž
空糞ãçšãæå¹èé¢ç©1.0m2ã®æ¿çž®åšãäœè£œã
ãã
ãããè£
眮ãçšããŠãè
¹æ°ŽåŠçãè¡ãªã€ããç
æ§æ£è
ã®è
¹æ°Žã§ç·èçœæ¿åºŠ2.4ïœïŒdlãã«ã€ããŠ
è
¹æ°Žç©¿åºåŸãå§åå¶åŸ¡ããªãã60mlïŒmin.ã§ïŒ
æé30åã«ãããäžéšå埪ç°ããã€ã€éãã次
ãã§æ¿çž®åšãéãç·èçœæ¿åºŠã2.5åã«æ¿çž®ãã
ã¹ãå§åå¶åŸ¡ãã€ã€æäœããã
éåŸã®è
¹æ°Žã«ã€ããŠåæã®çµæã现èïŒç现
èçã¯æ€åºããããå®å
šã«é€å»ããããæçµèçœ
æ¿åºŠã6.0ïœïŒïœãšèšå®éãã§ãã€ãã[Table] As is clear from the examples and comparative examples shown in Table 1, the water permeability and pressure resistance after high-pressure steam sterilization of hollow fibers that satisfy the swelling degree Ï of 1.0âŠÏâŠ1.2 and the Young's modulus ratio T of Tâ§0.3. It had excellent characteristics. Example 4 Saponification degree 98.5%, PVA with DP2400 and molecular weight 1000
PEG (95%/PVA) was heated and dissolved at 100â, and PVA
Apply the spinning stock solution with a concentration of 16% through the annular nozzle.
Hollow fibers were obtained under extrusion normal conditions. Next, the obtained hollow fibers were treated with glutaraldehyde/H 2 SO 4 /
Na 2 SO 4 =3/30/200g/70â-5
After soaking for a time and crosslinking treatment, wash with water at room temperature and further at 85â.
PEG was removed by washing for 1 hour to form a microporous structure. Thereafter, the fibers were air-dried at room temperature to obtain dry hollow fibers. The outer diameter of the obtained hollow fiber was 800Ό, and the membrane thickness was 200Ό. The young modulus of the obtained hollow fiber is
Y 40 =7.0Kg, Y100 =6.2Kg, and Young's modulus ratio T was 0.89. A filtration device with an effective membrane area of 0.5 m 2 was fabricated using this hollow fiber, and high-pressure steam sterilization was repeated three times at 121°C for 20 minutes, and the performance fluctuations were observed, but the membrane performance was not impaired at all. When we observed the cross section of this dry hollow fiber using an electron microscope, we found that
It was observed that the particles had a uniform diameter and were evenly arranged in the cross section. The degree of swelling Ï was 1.04.
Using this hollow fiber, a filter device with an effective membrane area of 1.0 m 2 was created. In addition, as a concentration membrane, the ethylene content is 33 mol%.
EVA hollow fiber membrane for artificial kidney was used. A concentrator with an effective membrane area of 1.0 m 2 was fabricated using this hollow fiber. Ascites was treated using these devices. The total protein concentration in ascites of a cancerous patient was 2.4 g/dl. After paracentesis of the ascites, the total protein concentration was 2.4 g/dl, and the pressure was controlled at 60 ml/min.
The mixture was allowed to pass for 30 minutes with partial recirculation and then passed through a concentrator under pressure control to concentrate the total protein concentration by 2.5 times. As a result of analysis of the ascites after the procedure, no bacteria, cancer cells, etc. were detected and it was completely removed. The final protein concentration was also 6.0 g/d, as specified.
Claims (1)
äžã«é åãããŠããåäžå€å質æ§é ãæãããã€
ãã®èšæœ€åºŠÏãã1.0âŠÏâŠ1.2ãã€ã³ã°ã¢ãžãŠã©
ã¹æ¯ïŒŽãâ§0.3ïŒããã§ãããšã¯100âåã³40
âæ°Žäžã«ãããã€ã³ã°ã¢ãžãŠã©ã¹ã®æ¯Y100ïŒY40
ãæå³ããïŒã§ãã105ã140âã§é«å§èžæ°æ» èå¯
èœãªããªããã«ã¢ã«ã³ãŒã«ç³»éžæééæ§èãå è
ããéåäœãšãäžèšéåäœã«ãã€ãŠéãã
ãè ¹æ°Žãæ¿çž®ããéžæééæ§èãå èããæ¿çž®å
äœããæ§æãããããšãç¹åŸŽãšããè ¹æ°ŽåŠççšè£
眮ã1 It has a uniform porous structure in which micropores with an average pore diameter of 0.01 to 2ÎŒ are uniformly arranged in the cross section, and its degree of swelling Ï is 1.0âŠÏâŠ1.2, and the Young's modulus ratio T is Tâ§0.3 (where T means 100â and 40
Young modulus ratio in °C water Y 100 / Y 40
), which is equipped with a polyvinyl alcohol-based permselective membrane that can be autoclaved at 105 to 140°C, and a permselective membrane that concentrates the ascites passed through the perunit. An apparatus for treating ascites, characterized by comprising a concentration unit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2572478A JPS54118699A (en) | 1978-03-06 | 1978-03-06 | Device for treating abdominal dropsy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2572478A JPS54118699A (en) | 1978-03-06 | 1978-03-06 | Device for treating abdominal dropsy |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS54118699A JPS54118699A (en) | 1979-09-14 |
JPS6236705B2 true JPS6236705B2 (en) | 1987-08-08 |
Family
ID=12173741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2572478A Granted JPS54118699A (en) | 1978-03-06 | 1978-03-06 | Device for treating abdominal dropsy |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS54118699A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56110625A (en) * | 1980-02-05 | 1981-09-01 | Takeda Chem Ind Ltd | Separating method of blood plasma and apparatus for the same |
JPH11302973A (en) * | 1998-04-22 | 1999-11-02 | Kuraray Co Ltd | Polyvinyl alcohol-based hollow yarn with excellent biocompatibility nd its production |
-
1978
- 1978-03-06 JP JP2572478A patent/JPS54118699A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS54118699A (en) | 1979-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4402940A (en) | Method for treating blood plasma employing a hollow fiber membrane | |
EP0569229A1 (en) | High efficiency removal of low density lipoprotein-cholesterol from whole blood | |
US4839055A (en) | Method for treating blood and apparatus therefor | |
JPWO2002009857A1 (en) | Modified hollow fiber membrane | |
US4741927A (en) | Production of cellulose dialysis membrane with improved biocompatibility | |
JPH0553528B2 (en) | ||
US4176070A (en) | Semi-permeable membranes of regenerated cuprammonium cellulose and method for heat sterilization thereof in physiological saline | |
JP3216910B2 (en) | Porous hollow fiber membrane | |
WO2000027447A1 (en) | Blood purifying apparatus | |
JPS6236705B2 (en) | ||
DE19750527C2 (en) | Cellulosic separation membrane | |
JP7035537B2 (en) | Separation membrane module | |
JP4352709B2 (en) | Polysulfone-based semipermeable membrane and artificial kidney using the same | |
JPH0370539B2 (en) | ||
CN116829576A (en) | Method for preparing controllable high-concentration silk fibroin solution by tangential flow ultrafiltration technology | |
JPH0135681B2 (en) | ||
CN114653222A (en) | Low-nonspecific adsorption virus removal filter membrane and preparation method thereof | |
JP4381058B2 (en) | Hollow fiber blood purifier with excellent blood compatibility | |
JP2003010322A (en) | Hollow fiber membrane for hemocatharsis, method for manufacturing the same, and blood purifier | |
JP2010233987A (en) | Blood purifier | |
JPH01254204A (en) | Method for removing virus | |
JPH0143562B2 (en) | ||
JP3147343B2 (en) | Method for producing hydrophilic filter material | |
JP2005074019A (en) | Hollow fiber type blood purification membrane | |
JPH0429409B2 (en) |